BRPI0412664A - método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth) - Google Patents

método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)

Info

Publication number
BRPI0412664A
BRPI0412664A BRPI0412664-5A BRPI0412664A BRPI0412664A BR PI0412664 A BRPI0412664 A BR PI0412664A BR PI0412664 A BRPI0412664 A BR PI0412664A BR PI0412664 A BRPI0412664 A BR PI0412664A
Authority
BR
Brazil
Prior art keywords
risk
hyperproliferation
treating
parathyroid hormone
skin cells
Prior art date
Application number
BRPI0412664-5A
Other languages
English (en)
Inventor
Paul Morley
James F Whitfield
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of BRPI0412664A publication Critical patent/BRPI0412664A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

"MéTODO PARA TRATAR UMA CONDIçãO CARACTERIZADA POR HIPERPROLIFERAçãO DE CéLULAS DA PELE EM UM INDIVìDUO EM RISCO OU PORTADOR DESSA CONDIçãO E UTILIZAçãO DE UMA QUANTIDADE TERAPEUTICAMENTE EFETIVA DE UM ANáLOGO CìCLICO DE HORMÈNIO DE PARATIREóIDE HUMANO (hPTH)". A presente invenção proporciona métodos para o tratamento de condições caracterizadas por hiperproliferação de células da pele, pela administração a um indivíduo com necessidade da mesma de um análogo cíclico de hormónio de paratireóide humano.
BRPI0412664-5A 2003-07-15 2004-07-09 método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth) BRPI0412664A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48751303P 2003-07-15 2003-07-15
PCT/CA2004/001003 WO2005007184A2 (en) 2003-07-15 2004-07-09 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells

Publications (1)

Publication Number Publication Date
BRPI0412664A true BRPI0412664A (pt) 2006-09-26

Family

ID=34079378

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412664-5A BRPI0412664A (pt) 2003-07-15 2004-07-09 método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)

Country Status (8)

Country Link
US (1) US20050065071A1 (pt)
EP (1) EP1644017A2 (pt)
JP (1) JP2007533596A (pt)
CN (1) CN1822853A (pt)
AU (1) AU2004257362A1 (pt)
BR (1) BRPI0412664A (pt)
CA (1) CA2529777A1 (pt)
WO (1) WO2005007184A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US20090042774A1 (en) * 2005-09-06 2009-02-12 Paul Morley Parathyroid hormone analogues and methods of use
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1984260A (en) * 1930-11-10 1934-12-11 Allen & Hanburys Ltd Process for preparing liquids containing active principles or hormones from parathyroid glands
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
US5120831A (en) * 1985-02-08 1992-06-09 Procyte Corporation Metal-peptide compositions
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5556940A (en) * 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5744128A (en) * 1995-05-03 1998-04-28 Holick; Michael F. Use of emu oil for stimulating skin and hair growth
US6242212B1 (en) * 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US5928884A (en) * 1996-02-09 1999-07-27 Croce; Carlo M. FHIT proteins and nucleic acids and methods based thereon
WO1998051324A1 (en) * 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Peptide parathyroid hormone analogs
US5942399A (en) * 1998-05-06 1999-08-24 Incyte Pharmaceuticals, Inc. Amino acid permease homolog
AU1918300A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Amino-terminal modified parathyroid hormone (pth) analogs
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
YU95102A (sh) * 2000-06-22 2005-11-28 Pfizer Products Inc. Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
EP1349564A2 (en) * 2000-06-22 2003-10-08 HOLICK, Michael F Regulation of cellproliferation and differentiation using topically applied peptides
US20040022838A1 (en) * 2001-06-20 2004-02-05 Holick Michael F. Regulation of cell proliferation and differentiation using topically applied peptides
AU2001296585A1 (en) * 2000-10-06 2002-04-15 Michael F. Holick Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
AU2002319049B2 (en) * 2001-07-19 2007-10-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Also Published As

Publication number Publication date
CN1822853A (zh) 2006-08-23
EP1644017A2 (en) 2006-04-12
AU2004257362A1 (en) 2005-01-27
JP2007533596A (ja) 2007-11-22
US20050065071A1 (en) 2005-03-24
CA2529777A1 (en) 2005-01-27
WO2005007184A2 (en) 2005-01-27
WO2005007184A3 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
Yamaoka et al. Study on biologic effects of radon and thermal therapy on osteoarthritis
EG26731A (en) Equivalent human antibodies as IFN-ادات antagonists and act as selective inhibitors of IFN- ر
DE602004030353D1 (de) Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung
DE69814917D1 (de) Transdermale therapeutische vorrichtung mit capsaicin und seinen analogen
DE69841907D1 (de) Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
WO2005100392A3 (en) Treatment of neuropathic pain with zinc finger proteins
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE602005013422D1 (de) Formulierungen mit ceramiden und/oder pseudoceramiden und (alpha-)bisabolol zur behandlung von hautschäden
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
ATE359846T1 (de) Abdeckung und applikator für ein teil eines säugetierkörpers
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ATE300288T1 (de) Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
BR0306306A (pt) Composição contendo extrato de matricária e uso desta
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
DK0951553T3 (da) Adenovirus-E4-proteiner til induktion af celledød
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
BRPI0412664A (pt) método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
MXPA03002160A (es) Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
BRPI0520672A2 (pt) composição formulada para administração tópica à pele e método para melhorar as condições da pele
Yamaguchi et al. Mechanoreceptors, nociceptors, and orthodontic tooth movement
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]